Price loading...

FIGHTING LUNG CANCER THROUGH THE HER FA (Cancer Etiology, Diagnosis and Treatments)

Oncology

Price data last checked 108 day(s) ago - refreshing...

View at Amazon

Price History & Forecast

No Price Data Available

Price history will appear here once data is collected from Amazon.

Price Distribution

No price data available for histogram

Description

Lung cancer is the most common and most lethal malignancy world-wide, causing 1.4 million diseases every year. Half of non-small cell lung cancers (NSCLC) are diagnosed at such an advanced stage that a cure cannot be considered a realistic aim, and over 75% of cases selected for a curative treatment eventually relapse within five years. The 5-year overall survival rates are less than 20% for NSCLC patients. As a disease, NSCLC demands our maximum abilities as researchers, physicians, and care-givers, and a continuous updating of our knowledge. Conventional chemotherapy for advanced NSCLC does not provide a great long-term benefit in terms of survival. Accordingly, a different therapeutic approach has to be explored. The human epidermal growth factor family of surface receptors (HER) became a critical target to be investigated. The epidermal growth factor receptor (EGFR) is over-expressed in over 80% of non-small cell lung cancer. The presence of sensitising conformational mutations in the EGFR increases the efficacy of modern tyrosine kinase inhibitors against its inner portion (EGFR-TKI). The EGFR-TKIs greatly prolong disease-free survival of those patients harbouring sensitising EGFR mutations, and have been suggested as an essential tool in the therapeutic repertoire. This volume aims to serve as an updated compendium of biology and applications of anti-EGFR therapies, and offers a look at the future of anti-HER therapy in lung cancer. This volume exhaustively reviews and discusses: 1) the nature and significance of activating EGFR mutations, and those clinical and pathological phenomena related to HER alterations; 2) the most common laboratory methodologies to study EGFR, and the future of HER analysis; 3) the right time to analyse EGFR mutations and evolutionary changes in the HER; 4) EGFR-TKI application in unselected and selected NSCLC patients; 5) upcoming anti-HER therapies; 6) the eventual role of anti-HER therapies in early NSCLC; 7) mechanisms of acquired resistance to anti-HER therapies, and experimental and conventional strategies to bypass them; 8) the application of anti-HER therapies in other malignancies. This book is an indispensable handbook for all those specialists devoted to the diagnosis and management of lung cancer.

Product Specifications

Format: hardcover
ASIN: 1633210928
Category: Books > Subjects > Health, Family & Lifestyle > Medical & Healthcare Practitioners > Internal Medicine > Diseases & Disorders > Oncology
Domain: Amazon UK
Release Date: 01 September 2014
Listed Since: 20 April 2014

Barcode

No barcode data available

FIGHTING LUNG CANCER THROUGH THE HER FA (Cancer Etiology, Diagnosis and Treatments)

Price History & Forecast

No Price Data Available

Price Distribution

Description

Product Specifications

Barcode

Similar Products You Might Like

Overcoming Resistance to EGFR Inhibitors in EGFR-Mutant NSCLC (Volume 19) (Cancer Sensitizing Agents for Chemotherapy, Volume 19)

Lung Cancer Treatment (Cancer Etiology, Diagnosis and Treatments)

Lung Cancer: An Evidence-Based Approach to Multidisciplinary Management

Lung Cancer: A Comprehensive Overview (Cancer Etiology, Diagnosis and Treatments)

Springer - Lung Cancer: Treatment and Research: 170 Book

Advances in Respiratory Cancerogenesis: 911 (Advances in Experimental Medicine and Biology, 911)

Lung Cancer: Volume 1: Molecular Pathology Methods and Reviews: 74 (Methods in Molecular Medicine, 74)

Lung Cancer: A Comprehensive Guide for the Clinician (Respiratory Medicine)

Lung Cancer: A Comprehensive Guide for the Clinician (Respiratory Medicine)

Methods of Cancer Diagnosis, Therapy and Prognosis: Breast Carcinoma: 1

Molecular Determinants of Head and Neck Cancer (Current Cancer Research)

McGraw-Hill Lung Cancer: Standards of Care (Hematology/Oncology)

Lung Cancer: Volume 2: Diagnostic and Therapeutic Methods and Reviews: 75 (Methods in Molecular Medicine, 75)

Cancer Drug Resistance (Cancer Drug Discovery and Development)

Targeted Therapies for Lung Cancer (Current Cancer Research)

Lung Cancer: Treatment and Research: 170

Drug Resistant Neoplasms (Cancer Etiology Diagnosis and Treatment Series)

Lung Cancer and Personalized Medicine: Current Knowledge and Therapies: 893 (Advances in Experimental Medicine and Biology, 893)

Gastric Cancer In The Precision Medicine Era: Diagnosis and Therapy (Current Clinical Pathology)

Humana Combination Cancer Therapy: Modulators and Potentiators

Squamous cell Carcinoma: Molecular Therapeutic Targets

Early-stage Lung Cancer: Screening and Management

Lung Imaging and Computer Aided Diagnosis

Combination Cancer Therapy: Modulators and Potentiators (Cancer Drug Discovery and Development)